- Expected overall cash savings of $75 million through 2025
- New executive management team in place
SAN DIEGO, July 24, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced a cost reduction plan and a corporate restructuring, following a strategic review of the business conducted by the new management team. These actions are expected to result in cash savings of approximately $75 million through 2025, inclusive of $45 million in operational savings, and continue Heron's progression towards a streamlined organization focused on commercial execution, enabling it to take a crucial step towards achieving profitability.
Read more at prnewswire.com